Genetically Targeted Technologies and the MINI Act

Streamed live on June 5 at 12 pm ET

Jump to: Resources | Take Action

Agenda

Part I: Cardiovascular Health Trends

Part II: Policies Impacting Cardiovascular Research and Development

Part III: The Promise of Genetically Targeted Technologies

Part IV: The MINI Act - A Targeted Fix

Q&A

Speakers

Featured
Michael Gibson, MS, MD
Michael Gibson, MS, MD

Dr. Gibson pioneered our understanding of the open artery and the open microvasculature hypothesis in the setting of heart attack. As an innovator, Gibson invented measures of coronary blood flow that are widely used today (the TIMI frame count (cited 2,131 times), the TIMI myocardial perfusion grade (cited 1,089 times).

Gibson is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School.

Chris Kelly
Chris Kelly

Chris Kelly leads the health portfolio for Senator Marsha Blackburn of Tennessee. He advises the Senator’s policy and oversight efforts on the Senate Finance Committee. Previously, he was an associate for a political strategies firm advising multiple federal, state, and local campaigns and has worked on Capitol Hill for over five years. Mr. Chris Kelly graduated Magna Cum Laude from Middle Tennessee State University with a degree in Political Science and a minor in History and Political and Civil Engagement.

Ryan Gough
Ryan Gough

Ryan Gough is a seasoned advocacy and campaign professional who understands how important the details are when the camera lights come on and what it means to put points on the board. He currently serves as Executive Director of the Partnership to Advance Cardiovascular Health (PACH) where he regularly convenes influential stakeholders to address access barriers and improve awareness about cardiovascular disease.

Learn More

Take Action

contact your legislator

Innovation expands patients’ treatment options, creating greater opportunity for improved quality of life. The MINI Act (S.476 | H.R.5547) would incentivize continued innovation. Ask your legislator to support it.

SOCIAL MEDIA TOOLKIT

Use this suggested copy to join the conversation on social media.

Hashtags: #GTTs #MINIAct #cardio #PassMINIAct #heart

Tags: @advcardiohealth 

  • Patients can’t sacrifice innovation like genetically targeted technologies. It’s time to #PassMINIAct to allow more time for research, investment and infrastructure for #GTTs. https://bit.ly/4bNC5ws

  • The #MINIAct encourages ongoing medical innovation such as genetically targeted technologies for #heart patients and would make it easier for them to adhere to life-saving treatments. https://bit.ly/3x3M7dP

  • Genetically targeted technologies address diseases at the genetic level. But for more patients to benefit, Congress needs to pass the bipartisan #MINIAct. #GTTs #PassMINIAct https://bit.ly/3XwfS1R

  • The #MINIAct would allow more time for research, investment and infrastructure in the development of novel therapies for heart patients. Contact your legislator and ask them to #PassMINIAct today: https://bit.ly/3VxeSck

  • Game-changing medical technology is on the line. Genetically targeted technologies can reduce patients' number of pharmacy visits, simplify medication routines and ultimately improve patients' #heart health management. #cardio #GTTs https://bit.ly/4bNC5ws